Novo Nordisk A/S (ADR)  

(Public, NYSE:NVO)   Watch this stock  
Find more results for NVO
41.59
-0.21 (-0.50%)
After Hours: 41.70 +0.11 (0.25%)
Sep 30, 5:16PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 41.27 - 41.86
52 week 41.27 - 59.00
Open 41.58
Vol / Avg. 5.65M/2.81M
Mkt cap 80.64B
P/E 19.54
Div/yield 0.45/2.18
EPS 2.13
Shares 1.96B
Beta 0.77
Inst. own 10%

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 36.30% 32.30%
Operating margin 45.51% 45.81%
EBITD margin - 46.35%
Return on average assets 46.86% 41.29%
Return on average equity 100.12% 79.90%
Employees 42,265 -
CDP Score - 100 B

Address

Novo Alle 1
BAGSVAERD, 2880
Denmark
+45-44-448888 (Phone)
+45-44-436633 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company's business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. It offers a range of diabetes product, including new generation insulins and a portfolio of modern insulin. It provides Saxenda, which is a product to treat obesity and is available in Denmark, Italy and Canada. Its other products/compounds include Xultophy, Semaglutide (NN9535), Faster-acting insulin aspart (NN1218), N9-GP (NN7999), N8-GP (NN7088) and NN8640 Once-weekly human growth hormone.

Officers and directors

Goran A. Ando M.D. Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Lars Rebien Soerensen President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Jeppe Christiansen Vice Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Jesper Brandgaard Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Maziar Mike Doustdar Executive Vice President, International Operations
Age: 45
Bio & Compensation  - Reuters
Lars Fruergaard Joergensen President, Chief Executive Officer
Age: 49
Bio & Compensation  - Reuters
Mads Krogsgaard Thomsen Chief Science Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Jakob Riis Executive Vice President, Head of North America Operations
Age: 50
Bio & Compensation  - Reuters
Henrik Ehlers Wulff Executive Vice President, Product Supply
Age: 45
Bio & Compensation  - Reuters
Brian Daniels M.D. Director
Age: 56
Bio & Compensation  - Reuters